As the leading patient recruitment service provider for cancer clinical trials, DAVA Oncology focuses its patient recruitment efforts on raising awareness of clinical trials among clinical trial investigators, research staff, clinical staff and referring physicians, thus helping to ensure that patients are offered the opportunity to participate in clinical trials. DAVA provides services that extend from site identification and study start-up to trial enrollment and patient retention. At DAVA’s services are focused on the overall goal of clinical trial acceleration. DAVA also partners with traditional patient recruitment companies to develop patient-focused approaches to enhancing enrollment such as posters, brochures, internet outreach and media campaigns when appropriate.

Our core strength is our staff of board certified medical oncologists who are able to quickly interpret evolving and increasingly complex body of oncology scientific information and translate this knowledge into accelerated clinical trial execution. We are the only provider of direct physician to physician tactical patient recruitment services. Our ultimate goal is to expedite the process of bringing new cancer therapies to physicians and their patients. Since 2007, we have worked with over 42 pharmaceutical companies on over 225 projects. These include relationships with large pharmaceutical companies as well as large, medium and small biotech companies.

Whether you need a “rescue strategy” for a trial that is enrolling slowly or you have a trial that you know will be difficult to enroll from the beginning, DAVA can provide the medical oncology support and the tools necessary for your trial to succeed. Across the board, DAVA’s unique patient recruitment strategies have increased clinical trial enrollment by 30-70%, allowing cancer clinical trials to enroll on or ahead of schedule and ultimately provide benefit to patients who desperately need life prolonging therapy. We look forward to the opportunity to discuss your trial’s needs with you!
DAVA CAN HELP!

FINDING THE RIGHT RESEARCH SITES IS THE SINGLE MOST IMPORTANT STEP IN ENSURING TIMELY COMPLETION OF A CLINICAL TRIAL. Each participating site must have access to the appropriate patient population, a thorough understanding and belief in the study rationale, as well as commitment to the study by keeping it ‘top-of-mind’. An important aspect of DAVA’s services is the identification and recommendation of high performing sites for clinical trials. DAVA prides itself on critically analyzing each site as well as choosing sites that can reliably recruit study subjects.

SITE RECOMMENDATION

SITE RECOMMENDATION CRITERIA:

- High caliber sites that are dedicated to clinical research
- Track record of high patient enrollment
- Committed to an accelerated opening timeline
- Excited about the study rationale
- Significant patient population

FINDING THE RIGHT RESEARCH SITES IS THE SINGLE MOST IMPORTANT STEP IN ENSURING TIMELY COMPLETION OF A CLINICAL TRIAL. Each participating site must have access to the appropriate patient population, a thorough understanding and belief in the study rationale, as well as commitment to the study by keeping it ‘top-of-mind’. An important aspect of DAVA’s services is the identification and recommendation of high performing sites for clinical trials. DAVA prides itself on critically analyzing each site as well as choosing sites that can reliably recruit study subjects.

Once DAVA fully evaluates a study site and is satisfied that the site meets all applicable criteria for selection, DAVA issues a formal recommendation to the study’s sponsor for its participation. Following approval of the site by the sponsor, DAVA assists with scheduling any additional required visits and helps answer any additional questions the investigator or site research staff might have.

DAVA’s Accrual Workshops™, which are facilitated by one of DAVA’s oncologists, are designed to engage investigators and research staff in interactive, case-based learning activities to enhance accrual. These three to four-hour programs begin with the site attendees presenting their site demographics, including standards of care, referral patterns and accrual potential to their peers. Sites are also asked to present case studies in order to identify appropriate patients for the trial.

THE CORNERSTONE OF DAVA’S ABILITY TO FACILITATE ENROLLMENT IN CLINICAL TRIALS IS OUR RELATIONSHIP WITH CLINICAL TRIAL INVESTIGATORS AND RESEARCH STAFF. DAVA provides ongoing support to clinical trials through phone, e-mail and site visits. In the course of these interactions, our medical oncologists discuss the trial’s status, diagnose barriers to recruitment and work directly with investigators and research staff to identify strategic actions to overcome these barriers. The ongoing nature of these interactions leads to familiarity of the investigator and research staff with DAVA’s physicians and provides the repeat messaging that is critical to keeping clinical trial enrollment ‘top-of-mind’ with investigators.

DAVA’s Accrual Workshops™, which are facilitated by one of DAVA’s oncologists, are designed to engage investigators and research staff in interactive, case-based learning activities to enhance accrual. These three to four-hour programs begin with the site attendees presenting their site demographics, including standards of care, referral patterns and accrual potential to their peers. Sites are also asked to present case studies in order to identify appropriate patients for the trial.

PHYSICIAN-FOCUSED PATIENT RECRUITMENT

CASE STUDY

Case #3: 70W with ER-/HER-2+ MBC progressing after trastuzumab

<table>
<thead>
<tr>
<th>HISTORY</th>
</tr>
</thead>
<tbody>
<tr>
<td>70 yr old woman initially presented with a positive mammogram. Biopsy demonstrated ER-/HER-2+ Positive IDC. MRM on 6/17/06 demonstrated a 3.5 cm mass with 3/12 + LN. Treated with TCH x 6 then 1 year of trastuzumab ending 7/07. On 10/08 she developed pain in the back. Bone scan demonstrated multiple bony disease with biopsy confirming HER-2+ MBC.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RECURRENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treated with 10 cycles of paclitaxel and trastuzumab then developed increased RUQ pain and CT demonstrated new liver metastasis.</td>
</tr>
</tbody>
</table>

For this patient, when would you discuss the study trial?

Would you continue trastuzumab and change chemotherapy?

For this patient, when would you discuss the study trial?

Would you continue trastuzumab and change chemotherapy?

For this patient, when would you discuss the study trial?